SIOX Sio Gene Therapies Inc

Price (delayed)

$0.33

Market cap

$24.33M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.98

Enterprise value

-$38.06M

Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Its current pipeline of clinical-stage candidates includes the ...

Highlights
The debt has surged by 102% year-on-year but it has declined by 6% since the previous quarter
SIOX's net income has dropped by 122% year-on-year and by 16% since the previous quarter
The company's EPS has shrunk by 58% YoY and by 21% QoQ

Key stats

What are the main financial stats of SIOX
Market
Shares outstanding
73.74M
Market cap
$24.33M
Enterprise value
-$38.06M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.4
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$71.6M
EBITDA
-$70.94M
Free cash flow
-$61.04M
Per share
EPS
-$0.98
Free cash flow per share
-$0.83
Book value per share
$0.82
Revenue per share
$0
TBVPS
$1.03
Balance sheet
Total assets
$75.08M
Total liabilities
$14.73M
Debt
$2.52M
Equity
$60.35M
Working capital
$58.73M
Liquidity
Debt to equity
0.04
Current ratio
5.52
Quick ratio
4.99
Net debt/EBITDA
0.88
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-71.8%
Return on equity
-82.3%
Return on invested capital
-84,986.4%
Return on capital employed
-115.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SIOX stock price

How has the Sio Gene Therapies stock price performed over time
Intraday
-8.66%
1 week
-10.08%
1 month
3.13%
1 year
-87.4%
YTD
-74.42%
QTD
-50.75%

Financial performance

How have Sio Gene Therapies's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$71.56M
Net income
-$71.89M
Gross margin
N/A
Net margin
N/A
SIOX's net income has dropped by 122% year-on-year and by 16% since the previous quarter
The operating income has plunged by 70% YoY

Growth

What is Sio Gene Therapies's growth rate over time

Valuation

What is Sio Gene Therapies stock price valuation
P/E
N/A
P/B
0.4
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has shrunk by 58% YoY and by 21% QoQ
The price to book (P/B) is 93% lower than the 5-year quarterly average of 5.4 and 69% lower than the last 4 quarters average of 1.3
The equity has dropped by 51% year-on-year and by 21% since the previous quarter

Efficiency

How efficient is Sio Gene Therapies business performance
The ROE has plunged by 116% YoY and by 37% from the previous quarter
The company's return on assets has shrunk by 113% YoY and by 34% QoQ

Dividends

What is SIOX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SIOX.

Financial health

How did Sio Gene Therapies financials performed over time
The current ratio has plunged by 55% YoY and by 7% from the previous quarter
The company's quick ratio has shrunk by 55% YoY and by 9% QoQ
The debt is 96% smaller than the equity
The debt has surged by 102% year-on-year but it has declined by 6% since the previous quarter
The equity has dropped by 51% year-on-year and by 21% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.